[go: up one dir, main page]

MXPA02012198A - Encapsulation of plasmid dna (lipogenestm). - Google Patents

Encapsulation of plasmid dna (lipogenestm).

Info

Publication number
MXPA02012198A
MXPA02012198A MXPA02012198A MXPA02012198A MXPA02012198A MX PA02012198 A MXPA02012198 A MX PA02012198A MX PA02012198 A MXPA02012198 A MX PA02012198A MX PA02012198 A MXPA02012198 A MX PA02012198A MX PA02012198 A MXPA02012198 A MX PA02012198A
Authority
MX
Mexico
Prior art keywords
encapsulated
oligonucleotides
negatively
plasmids
charged
Prior art date
Application number
MXPA02012198A
Other languages
Spanish (es)
Inventor
Teni Boulikas
Original Assignee
Teni Boulikas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teni Boulikas filed Critical Teni Boulikas
Publication of MXPA02012198A publication Critical patent/MXPA02012198A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

A method is disclosed for encapsulating plasmids, oligonucleotides or negatively-charged drugs into liposomes having a different lipid composition between their inner and outer membrane bilayers and able to reach primary tumors and their metastases after intravenous injection to animals and humans. The formulation method includes complex formation between DNA with cationic lipid molecules and fusogenic/NLS peptide conjugates composed of a hydrophobic chain of about 10-20 amino acids and also containing four or more histidine residues or NLS at their one end. The encapsulated molecules display therapeutic efficacy in eradicating a variety of solid human tumors including but not limited to breast carcinoma and prostate carcinoma. Combination of the plasmids, oligonucleotides or negatively-charged drugs with other anti-neoplastic drugs (the positively-charged cis-platin, doxorubicin) encapsulated into liposomes are of therapeutic value. Also of therapeutic value in cancer eradication are combinations of encapsulated the plasmids, oligonucleotides or negatively-charged drugs with HSV-tk plus encapsulated ganciclovir.
MXPA02012198A 2000-06-09 2001-06-08 Encapsulation of plasmid dna (lipogenestm). MXPA02012198A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21092500P 2000-06-09 2000-06-09
PCT/US2001/018657 WO2001093836A2 (en) 2000-06-09 2001-06-08 Encapsulation of polynucleotides and drugs into targeted liposomes

Publications (1)

Publication Number Publication Date
MXPA02012198A true MXPA02012198A (en) 2004-08-19

Family

ID=22784880

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02012198A MXPA02012198A (en) 2000-06-09 2001-06-08 Encapsulation of plasmid dna (lipogenestm).

Country Status (8)

Country Link
EP (1) EP1292284A2 (en)
JP (1) JP2003535832A (en)
CN (2) CN1254234C (en)
AU (2) AU2001275423B2 (en)
CA (1) CA2411542A1 (en)
MX (1) MXPA02012198A (en)
TW (1) TWI292324B (en)
WO (1) WO2001093836A2 (en)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60144561D1 (en) * 2000-06-16 2011-06-16 Serodus As N AND / OR C TERMINAL WITH SHORT-LOADED PEPTIDE SEQUENCES MODIFIED PEPTIDES
CA2412513A1 (en) * 2000-06-22 2001-12-27 San Diego State University Foundation Modulators of recombination and methods for producing and using the same
CA2420350C (en) * 2000-08-25 2010-07-13 Aventis Pharmaceuticals Inc. Membrane penetrating peptides and uses thereof
GB0103110D0 (en) 2000-08-25 2001-03-28 Aventis Pharma Inc A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
AU3652602A (en) * 2000-11-15 2002-05-27 Us Gov Health & Human Serv Sol-fusin: use of gp64-6his to catalyze membrane fusion
SE0101702D0 (en) 2001-05-15 2001-05-15 Ardenia Investments Ltd Novel potentiating compounds
DE60231549D1 (en) 2001-12-03 2009-04-23 Dor Biopharma Inc STABILIZED REVERSE MICRO-COMPOSITIONS AND THEIR USE
US20040052928A1 (en) 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
AU2003278807A1 (en) 2002-03-01 2004-08-13 Bracco International B.V. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
JP2003286198A (en) * 2002-03-29 2003-10-07 Japan Science & Technology Corp Therapeutic medicine using protein hollow nanoparticle expression growth factor, and the like
JP2003286199A (en) * 2002-03-29 2003-10-07 Japan Science & Technology Corp Therapeutic medicine for hepatic disease using protein hollow nanoparticle
CA2486007C (en) * 2002-05-15 2011-11-22 California Pacific Medical Center Delivery of nucleic acid-like compounds
EP1530465B2 (en) 2002-06-26 2015-12-16 MediGene AG Method of producing a cationic liposomal preparation comprising a lipophilic compound
DK1519714T3 (en) 2002-06-28 2011-01-31 Protiva Biotherapeutics Inc Method and apparatus for preparing liposomes
US20050232984A1 (en) * 2002-08-23 2005-10-20 Heinrich Haas Non-vesicular cationic lipid formulations
US7491699B2 (en) 2002-12-09 2009-02-17 Ramot At Tel Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
ATE426575T1 (en) 2003-01-07 2009-04-15 Univ Ramot PEPTIDE ANOSTRUCTURES CONTAINING FOREIGN MATERIAL AND METHOD FOR PRODUCING THE SAME
WO2004082626A2 (en) * 2003-03-18 2004-09-30 Ethicon, Inc. Aromatase inhibitor diagnosis and therapy
CA2530927A1 (en) 2003-06-30 2005-01-06 Tel Aviv University Future Technology Development L.P. Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
WO2005031362A2 (en) 2003-10-02 2005-04-07 Ramot At Tel Aviv University Ltd. Novel antibacterial agents and methods of identifying and utilizing same
EP1793816B1 (en) 2004-08-19 2012-01-04 Tel Aviv University Future Technology Development L.P. Compositions for treating amyloid associated diseases
JP4810825B2 (en) * 2004-12-27 2011-11-09 東洋紡績株式会社 Lipase activity measuring method and measuring reagent
US20070014841A1 (en) * 2005-02-08 2007-01-18 Denis Martin Pharmaceutical compositions
JP5067733B2 (en) * 2005-03-09 2012-11-07 国立大学法人北海道大学 Lipid membrane structure capable of delivering target substance into mitochondria
EP1867726A4 (en) * 2005-03-24 2008-09-24 Univ Hokkaido Nat Univ Corp LIPOSOME CAPABLE OF RELEASING EFFICIENTLY A SUBSTANCE GIVEN IN THE CORE
EP1973928A2 (en) 2005-10-11 2008-10-01 Ramot at Tel-Aviv University Ltd. Self-assembled fmoc-ff hydrogels
CN100376680C (en) * 2005-11-01 2008-03-26 暨南大学 Double target effect gene chimeric recombinant and its construction method and application
EP1790657A1 (en) * 2005-11-24 2007-05-30 Technische Universität München pH-switchable transmembrane peptides as stimulators of membrane fusion
GR20060100144A (en) * 2006-03-03 2007-10-17 Cancer treatment using oxaliplatin encapsulated into liposomes and co-encapsulation into the liposome particle of more than one pharmaceutical preparations, or genes
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
KR101129509B1 (en) 2006-10-03 2012-04-13 알닐람 파마슈티칼스 인코포레이티드 Lipid containing formulations
CN101610759A (en) 2006-11-07 2009-12-23 美国政府卫生与公共服务部 Self-assembled nanoparticles composed of transmembrane peptides and their application for specific intratumoral delivery of anticancer drugs
EP2134365B1 (en) * 2007-03-21 2019-03-13 Effat Emamian Compositions and methods for inhibiting tumor cell growth
EP2170267A4 (en) * 2007-06-28 2011-04-27 Agency Science Tech & Res CATIONIC PEPTIDE FOR RELEASING AN AGENT IN A CELL
JP2009203174A (en) * 2008-02-26 2009-09-10 Hokkaido Univ Iontophoresis composition comprising protein-liposome complex
PL2279254T3 (en) 2008-04-15 2017-11-30 Protiva Biotherapeutics Inc. Novel lipid formulations for nucleic acid delivery
WO2010149785A1 (en) * 2009-06-26 2010-12-29 Universiteit Gent Cationic liposomes for the delivery of high molecular weight compounds
US8283333B2 (en) 2009-07-01 2012-10-09 Protiva Biotherapeutics, Inc. Lipid formulations for nucleic acid delivery
CN102038640B (en) * 2009-10-26 2013-11-13 石药集团中奇制药技术（石家庄）有限公司 Liposome medicament containing cholesterol PEG modifier and preparation method thereof
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
DK2590626T3 (en) 2010-07-06 2016-01-25 Glaxosmithkline Biolog Sa Liposomes with lipids having a favorable pKa of RNA for bringing
US9801897B2 (en) 2010-07-06 2017-10-31 Glaxosmithkline Biologicals Sa Delivery of RNA to trigger multiple immune pathways
SI2591114T1 (en) 2010-07-06 2016-10-28 Glaxosmithkline Biologicals S.A. Immunisation of large mammals with low doses of rna
DK4066856T3 (en) 2010-08-31 2022-12-19 Glaxosmithkline Biologicals Sa Pegylated liposomes for delivery of immunogen-encoding RNA
US20140030292A1 (en) 2010-10-11 2014-01-30 Novartis Ag Antigen delivery platforms
JP5911503B2 (en) 2010-11-15 2016-04-27 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッドＲａｍｏｔ Ａｔ Ｔｅｌ Ａｖｉｖ Ｕｎｉｖｅｒｓｉｔｙ Ｌｔｄ． Dipeptide analogs for treating amyloid fibril formation-related conditions
US9303063B2 (en) 2011-03-18 2016-04-05 Duke University Peptide compounds for suppressing inflammation
US9018169B2 (en) * 2011-03-18 2015-04-28 Duke University Peptides for suppressing inflammation
US11896636B2 (en) 2011-07-06 2024-02-13 Glaxosmithkline Biologicals Sa Immunogenic combination compositions and uses thereof
EP2750707B1 (en) 2011-08-31 2018-10-24 GlaxoSmithKline Biologicals SA Pegylated liposomes for delivery of immunogen-encoding rna
CN104271590B (en) * 2012-01-24 2018-06-05 Inter-K私人有限公司 For the peptide agent of cancer treatment
US10100331B2 (en) 2012-10-29 2018-10-16 Agency For Science, Technology And Research Reagent for gene-drug therapeutics
CN103211762B (en) * 2013-04-11 2015-01-14 同济大学 Novel diagnosis and treatment integrated hybridization micelle and preparation method thereof
EP4501318A2 (en) 2014-04-23 2025-02-05 ModernaTX, Inc. Nucleic acid vaccines
BR112017006057B1 (en) * 2014-09-26 2023-11-21 Universidade Estadual Paulista Júlio De Mesquita Filho - Unesp Pharmaceutical composition based on prostaglandin J2 incorporated into micellar systems based on poloxamers to enhance analgesic and anti-inflammatory activities
MA45481A (en) 2015-06-10 2018-04-18 Univ Texas USE OF EXOSOMES FOR THE TREATMENT OF DISEASES
MX2018004918A (en) * 2015-10-22 2019-04-01 Modernatx Inc Herpes simplex virus vaccine.
JP7080826B2 (en) * 2016-05-16 2022-06-06 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム Cationic sulfonamide aminolipids and amphoteric zwitterionic aminolipids
EP3490560B1 (en) 2016-07-29 2025-01-22 Janssen Pharmaceutica, N.V. Niraparib for use in a method of treating prostate cancer
MA46584A (en) 2016-10-21 2019-08-28 Modernatx Inc HUMAN CYTOMEGALOVIRUS VACCINE
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
CN118374452A (en) 2017-08-25 2024-07-23 隆萨销售股份公司 Preparation of therapeutic exosomes using membrane proteins
MX2020006672A (en) 2017-12-28 2020-08-31 Codiak Biosciences Inc EXOSOMES FOR IMMUNO-ONCOLOGY AND ANTI-INFLAMMATORY THERAPY.
KR102617947B1 (en) * 2017-12-29 2023-12-27 쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 Conjugates and their preparation and uses
WO2020190750A1 (en) 2019-03-15 2020-09-24 Modernatx, Inc. Hiv rna vaccines
KR102101179B1 (en) * 2019-09-20 2020-05-15 건양대학교 산학협력단 Manufacturing Method of Nanocomplex for targeted theraphy in breast cancer stem cell(BCSC)
KR102164218B1 (en) * 2019-09-24 2020-10-12 코스맥스 주식회사 Multilayer cationic liposome for enhancing the skin penetration and preparation method thereof
JPWO2022045009A1 (en) * 2020-08-24 2022-03-03
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
CN117098541A (en) 2020-11-25 2023-11-21 阿卡格拉医药公司 Lipid nanoparticles for delivery of nucleic acids and related methods of use
CN114762679B (en) * 2021-01-13 2023-04-07 上海交通大学医学院 A kind of nanocomposite and its preparation method and application
CN113406957B (en) * 2021-05-19 2022-07-08 成都理工大学 Mobile robot autonomous navigation method based on immune deep reinforcement learning
CN113546180A (en) * 2021-05-25 2021-10-26 重庆医科大学 A kind of gene delivery vector with myocardial targeting and preparation method thereof
US20240336938A1 (en) * 2021-07-19 2024-10-10 Wuhan University Compositions and methods for effective delivery of polynucleotides to cells
KR20230046874A (en) * 2021-09-30 2023-04-06 (주)케어젠 Peptide Having Anti-Aging Activity and Uses Thereof
EP4230638A1 (en) * 2022-02-16 2023-08-23 Lipotrue, S.L. Peptides and compositions for use in cosmetics
CN114632062A (en) * 2022-03-21 2022-06-17 南京大学 Neutral liposome for delivering nucleic acid medicament and preparation method and application thereof
CN119562806A (en) 2022-05-25 2025-03-04 阿卡格拉医药公司 Lipid nanoparticles for delivery of nucleic acids and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635487A (en) * 1994-12-29 1997-06-03 Wolff; Jon A. Amphipathic, micellar delivery systems for biologically active polyions
US6120794A (en) * 1995-09-26 2000-09-19 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells
FR2754272B1 (en) * 1996-10-08 1998-11-13 Rhone Poulenc Rorer Sa PROCESS FOR THE PREPARATION OF COMPOSITIONS FOR TRANSFERRING NUCLEIC ACIDS
BR9813548A (en) * 1997-12-12 2000-10-10 Samyang Corp Biodegradable mixed polymeric micelles for gene distribution

Also Published As

Publication number Publication date
AU2001275423B2 (en) 2007-01-11
CN1444472A (en) 2003-09-24
AU7542301A (en) 2001-12-17
CA2411542A1 (en) 2001-12-13
EP1292284A2 (en) 2003-03-19
CN1981873A (en) 2007-06-20
JP2003535832A (en) 2003-12-02
WO2001093836A3 (en) 2002-10-03
TWI292324B (en) 2008-01-11
CN1254234C (en) 2006-05-03
WO2001093836A2 (en) 2001-12-13

Similar Documents

Publication Publication Date Title
MXPA02012198A (en) Encapsulation of plasmid dna (lipogenestm).
Antoniou et al. Stimulus-responsive liposomes for biomedical applications
Chen et al. Recent advances in subcellular targeted cancer therapy based on functional materials
ES2383516T3 (en) Photochemical internalization to deliver molecules in the cytosol
Yang et al. PEGylated liposomes with NGR ligand and heat-activable cell-penetrating peptide–doxorubicin conjugate for tumor-specific therapy
Ma et al. Future of nanotherapeutics: Targeting the cellular sub-organelles
Minko et al. Molecular targeting of drug delivery systems to cancer
GR20000100384A (en) Use of cisplatin and other drugs or genes encapsulated into liposomes for the treatment of human cancers
CN107920964B (en) Fusion liposome-coated porous silicon nanoparticles
KR102109188B1 (en) Temperature sensitive liposome comprising cationic lipid and use thereof
Han et al. Functional peptide-based nanoparticles for photodynamic therapy
Ko et al. Cationic liposomes loaded with proapoptotic peptide D-(KLAKLAK) 2 and Bcl-2 antisense oligodeoxynucleotide G3139 for enhanced anticancer therapy
Rajput et al. Bilosome: a bile salt based novel carrier system gaining interest in pharmaceutical research
AU2002220853A1 (en) Photochemical internalization for delivery of molecules into the cytosol
BRPI1015424B1 (en) COMPOSITION COMPRISING A CENDR ELEMENT AND A CO-COMPOSITION AND COMPOSITION FOR USE IN ENHANCING INTERNALIZATION, PENETRATION, OR BOTH OF A CO-COMPOSITION
US7741431B2 (en) Liposomes containing novel targeting and/or fusogenic peptides, preparations containing them and therapeutic use thereof
E. Wang et al. Development of NGR-based anti-cancer agents for targeted therapeutics and imaging
Yu et al. Recent advances in melittin-based nanoparticles for antitumor treatment: from mechanisms to targeted delivery strategies
Bolhassani Lipid-based delivery systems in development of genetic and subunit vaccines
Ravula et al. Gemini lipopeptide bearing an ultrashort peptide for enhanced transfection efficiency and cancer-cell-specific cytotoxicity
Zhang et al. Drug-bearing peptide-based nanospheres for the inhibition of metastasis and growth of cancer
Li et al. Smart liposomes for drug delivery
CN109432432A (en) Targeted to the building and application of endocytoplasmic reticulum nano medicament carrying system
WO1996040627A3 (en) Thiocationic lipids, pharmaceutical compositions and methods of use thereof
EP3743110B1 (en) Mrna molecule and photosensitizing agent for medical use

Legal Events

Date Code Title Description
GB Transfer or assignment
FG Grant or registration